Media stories about Rhythm Pharmaceuticals (NASDAQ:RYTM) have been trending somewhat positive on Sunday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Rhythm Pharmaceuticals earned a news impact score of 0.22 on Accern’s scale. Accern also gave media coverage about the company an impact score of 44.7847419574083 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern Sentiment’s analysis:
- Rhythm Pharmaceuticals (RYTM) Presents At 38th Annual Cowen and Company Healthcare Conference – Slideshow (seekingalpha.com)
- Rhythm Pharmaceuticals (RYTM) Stock Rating Upgraded by BidaskClub (americanbankingnews.com)
- Rhythm Pharmaceuticals (RYTM) Announces Quarterly Earnings Results (americanbankingnews.com)
- Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results (finance.yahoo.com)
- Diurnal Selects Worldwide Clinical Trials as Preferred CRO Provider (bizjournals.com)
RYTM has been the topic of several research reports. BidaskClub lowered Rhythm Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, December 29th. Needham & Company LLC restated a “buy” rating and set a $32.00 price target on shares of Rhythm Pharmaceuticals in a research note on Monday, February 26th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $31.25.
Rhythm Pharmaceuticals (NASDAQ:RYTM) last released its quarterly earnings data on Monday, March 12th. The company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.14. sell-side analysts predict that Rhythm Pharmaceuticals will post -2.3 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This article was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.tickerreport.com/banking-finance/3274968/rhythm-pharmaceuticals-rytm-given-news-impact-score-of-0-22.html.
Rhythm Pharmaceuticals Company Profile
Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.
Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.